Peak Bio, Inc. (PKBO) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Palo Alto, CA, United States. El CEO actual es Hoyoung Huh.
PKBO tiene fecha de IPO 2021-03-15, 6 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $520.31K.
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.
